Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib + HAIC (mFOLFOX vs ROX) in Advanced HCC
NCT05007587Phase 1Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jul 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of raltitrexed in hepatocellular carcinoma (HCC) (2 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoints: Objective Response Rate at 4 weeks and Disease Control Rate at 4 weeks. Status: unknown.
02
Drugs
raltitrexed
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05007587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05007587.